Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.

The study will examine vaccine safety, efficacy and immunity at lower doses. Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical ...

The US Food and Drug Administration has issued emergency use authorization (EUA) for the Covid-19 vaccine developed by Pfizer and BioNTech. After months of development, emergency use was authorized ...

The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said Thursday. The companies can now ...

Getting a COVID booster could save your life, even if you’ve had multiple prior infections and vaccinations. A study, published on Wednesday in the New England Journal of Medicine, showed that last ...

Vaccine efficacy against infection wanes, but does everyone need a 2nd booster? This is a MedPage Today story. As the U.S. experiences a dip in COVID-19 cases and mask mandates are being lifted, some ...

Add Yahoo as a preferred source to see more of our stories on Google. A health worker administers a Pfizer Covid-19 vaccine in Los Angeles, California, on 29 January 2022.Photograph: Shannon Stapleton ...